ID: ALA5290437

Max Phase: Preclinical

Molecular Formula: C20H18N4O2

Molecular Weight: 346.39

Associated Items:

Representations

Canonical SMILES:  COc1cccc(CNC(=O)c2c[nH]c3ccc(-c4cn[nH]c4)cc23)c1

Standard InChI:  InChI=1S/C20H18N4O2/c1-26-16-4-2-3-13(7-16)9-22-20(25)18-12-21-19-6-5-14(8-17(18)19)15-10-23-24-11-15/h2-8,10-12,21H,9H2,1H3,(H,22,25)(H,23,24)

Standard InChI Key:  PXASEBKCVVWWAC-UHFFFAOYSA-N

Associated Targets(Human)

Rho-associated protein kinase 2 6206 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 346.39Molecular Weight (Monoisotopic): 346.1430AlogP: 3.50#Rotatable Bonds: 5
Polar Surface Area: 82.80Molecular Species: NEUTRALHBA: 3HBD: 3
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 12.92CX Basic pKa: 2.28CX LogP: 2.66CX LogD: 2.66
Aromatic Rings: 4Heavy Atoms: 26QED Weighted: 0.52Np Likeness Score: -1.32

References

1. Feng Y, LoGrasso PV, Defert O, Li R..  (2016)  Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential.,  59  (6): [PMID:26486225] [10.1021/acs.jmedchem.5b00683]

Source